talnetant talnetant talnetant (sb-223,412) is a neurokinin 3 receptor antagonist developed by glaxosmithkline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo). its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued. talnetantclinical dataatc codenoneidentifiers iupac name 3-hydroxy-2-phenyl-n-(1-phenylpropyl)quinoline-4-carboxamide cas number174636-32-9 ypubchem cid133090iuphar/bps2124chemspider117450 nuniicz3t9t146kecha infocard100.236.526 chemical and physical dataformulac25h22n2o2molar mass382.463 g·mol−13d model (jsmol)interactive image smiles ccc(c1=cc=cc=c1)nc(=o)c2=c(c(=nc3=cc=cc=c32)c4=cc=cc=c4)o inchi inchi=1s/c25h22n2o2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28h,2h2,1h3,(h,27,29) nkey:biavgwdgijkwrm-uhfffaoysa-n n ny (what is this?) (verify)